HUMAN RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST PREVENTS ADRENOCORTICOTROPIN, BUT NOT INTERLEUKIN-6 RESPONSES TO BACTERIAL-ENDOTOXIN IN RATS

被引:47
|
作者
SCHOTANUS, K [1 ]
TILDERS, FJH [1 ]
BERKENBOSCH, F [1 ]
机构
[1] FREE UNIV AMSTERDAM,FAC MED,NEUROSCI RES INST,DEPT PHARMACOL,VAN DER BOECHORSTR 7,1081 BT AMSTERDAM,NETHERLANDS
关键词
D O I
10.1210/en.133.6.2461
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The present study was designed to analyze the role of endogenous interleukin-1 (IL-1) in the ACTH, corticosterone (CORT), and IL-6 responses of rats to bacterial endotoxin. Recombinant rat IL-1beta (rIL-1beta) when given ip resulted in dose-dependent increases in plasma ACTH, CORT, and IL-6 concentrations. Plasma ACTH and CORT responses could be induced by low rIL-1beta doses that did not elevate plasma IL-6 levels. The half-maximally effective dose of rIL-1beta was less than 0.6 mug/kg for the ACTH and CORT responses and higher than 2.5 mug/kg for the IL-6 response. Time-course studies indicated that plasma ACTH and CORT concentrations were already elevated 30 min after the injection of rIL-1beta (2.5 mug/kg, ip), with peak values after 1-2 h, followed by a subsequent decline. In contrast, plasma IL-6 concentrations became elevated 2 h after the injection of rIL-10. In another set of experiments, the administration of endotoxin resulted in a dose-dependent elevation of the plasma ACTH, CORT, and IL-6 concentrations. The dose-response characteristics for ACTH, CORT, and IL-6 were different. The half-maximally effective dose for the ACTH and CORT, and IL-6 responses were approximately 2.5 mug/kg and more than 10 mug/kg, respectively. Time courses of plasma ACTH, CORT, and IL-6 responses to endotoxin (2.5 mug/kg, ip) were similar, with peak values measured after 2 h. When given alone, the human IL-1 receptor antagonist (IL-1RA; 1 or 2.5 mg/kg, ip) did not affect resting plasma ACTH and CORT concentrations and reduced plasma IL-6 concentrations in one experiment. At a dose of 1 mg/kg, IL-1RA inhibited ACTH and IL-6 responses to rIL-1beta (2.5 mug/kg, ip) by 75% and 90%, respectively. Administration of IL-1RA (2.5 mg/kg, ip) 30 min after endotoxin (2.5 ug/kg, ip) completely prevented the ACTH response and partially inhibited the CORT response, but did not affect the IL-6 response measured 2.5 h after endotoxin administration. We conclude that 1) IL-1 receptors are involved in the ACTH and IL-6 responses to rat IL-1beta; 2) the ACTH response, but not the IL-6 response, to a low dose dose of endotoxin in rats requires IL-1 receptor activation by endogenous produced IL-1; and 3) circulating IL-6 is not a prime mediator involved in ACTH and CORT responses to low doses of rIL-1beta and endotoxin.
引用
收藏
页码:2461 / 2468
页数:8
相关论文
共 50 条
  • [41] INHIBITION OF INTERLEUKIN-1 BY AN INTERLEUKIN-1 RECEPTOR ANTAGONIST PREVENTS GRAFT-VERSUS-HOST DISEASE
    MCCARTHY, PL
    ABHYANKAR, S
    NEBEN, S
    NEWMAN, G
    SIEFF, C
    THOMPSON, RC
    BURAKOFF, SJ
    FERRARA, JLM
    BLOOD, 1991, 78 (08) : 1915 - 1918
  • [42] KIDNEY AS A MAJOR CLEARANCE ORGAN FOR RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST
    KIM, DC
    REITZ, B
    CARMICHAEL, DF
    BLOEDOW, DC
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (05) : 575 - 580
  • [43] The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
    Bresnihan, B
    BIODRUGS, 2001, 15 (02) : 87 - 97
  • [44] Interleukin-1 Receptor Antagonist
    Lennard, Andrew C.
    CRITICAL REVIEWS IN IMMUNOLOGY, 2017, 37 (2-6) : 531 - 559
  • [45] Interleukin-1 receptor antagonist
    Bresnihan, B
    Cunnane, G
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1998, 24 (03) : 615 - +
  • [46] INITIAL CRYSTALLOGRAPHIC ANALYSIS OF A RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN
    CLANCY, LL
    FINZEL, BC
    YEM, AW
    DEIBEL, MR
    STRAKALAITIS, NA
    BRUNNER, DP
    SWEET, RM
    EINSPAHR, HM
    ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 1994, 50 : 197 - 201
  • [47] The Prospect of Treating Rheumatoid Arthritis with Recombinant Human Interleukin-1 Receptor Antagonist
    Barry Bresnihan
    BioDrugs, 2001, 15 : 87 - 97
  • [48] Interleukin-1 family expression in human breast cancer: Interleukin-1 receptor antagonist
    Miller, LJ
    Kurtzman, SH
    Anderson, K
    Wang, YP
    Stankus, M
    Renna, M
    Lindquist, R
    Barrows, G
    Kreutzer, DL
    CANCER INVESTIGATION, 2000, 18 (04) : 293 - 302
  • [49] INTERLEUKIN-1 RECEPTOR ANTAGONIST
    AREND, WP
    ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 : 167 - 227
  • [50] Human interleukin-1β and interleukin-1 receptor antagonist secretion and velocity of tooth movement
    Iwasaki, LR
    Haack, JE
    Nickel, JC
    Reinhardt, RA
    Petro, TM
    ARCHIVES OF ORAL BIOLOGY, 2001, 46 (02) : 185 - 189